...
首页> 外文期刊>ACS Chemical Biology >Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48
【24h】

Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48

机译:阿维巴坦对D类碳青霉烯酶的选择性抑制和缓慢可逆性的分子基础:OXA-24和OXA-48的结构指导研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The Class D (or OXA-type) beta-lactamases have expanded to be the most diverse group of serine beta-lactamases with a highly heterogeneous beta-lactam hydrolysis profile and are typically resistant to marketed beta-lactamase inhibitors. Class D enzymes are increasingly found in multidrug resistant (MDR) Acinetobacter baumannii, Pseudomonas aeruginosa, and various species of the Enterobacteriaceae and are posing a serious threat to the clinical utility of beta-lactams including the carbapenems, which are typically reserved as the drugs of last resort. Avibactam, a novel non-beta-lactam beta-lactamase inhibitor, not only inhibits all class A and class C beta-lactamases but also has the promise of inhibition of certain OXA enzymes, thus extending the antibacterial activity of the beta-lactam used in combination to the organisms that produce these enzymes. X-ray structures of OXA-24 and OXA-48 in complex with avibactam revealed the binding mode of this inhibitor in this diverse class of enzymes and provides a rationale for selective inhibition of OXA-48 members. Additionally, various subunits of the OXA-48 structure in the asymmetric unit provide snapshots of different states of the inhibited enzyme. Overall, these data provide the first structural evidence of the exceptionally slow reversibility observed with avibactam in class D beta-lactamases. Mechanisms for acylation and deacylation of avibactam by class D enzymes are proposed, and the likely extent of inhibition of class D beta-lactamases by avibactam is discussed.
机译:D类(或OXA型)β-内酰胺酶已扩展为具有高度异质性β-内酰胺水解特性的丝氨酸β-内酰胺酶种类最多的组,并且通常对市售的β-内酰胺酶抑制剂具有抵抗力。 D类酶越来越多地出现在耐多药(MDR)的鲍曼不动杆菌,铜绿假单胞菌和肠杆菌科的各种物种中,并对包括碳青霉烯类在内的β-内酰胺类药物的临床应用构成严重威胁,后者通常被保留为最后一招。阿维巴坦(Avibactam)是一种新型的非β-内酰胺β-内酰胺酶抑制剂,不仅抑制所有的A类和C类β-内酰胺酶,而且有望抑制某些OXA酶,从而扩展了β-内酰胺的抗菌活性。与产生这些酶的生物体结合。 OXA-24和OXA-48与avibactam配合使用的X射线结构揭示了这种抑制剂在这种不同种类的酶中的结合模式,并为选择性抑制OXA-48成员提供了依据。此外,不对称单元中OXA-48结构的各种亚基提供了受抑制酶不同状态的快照。总体而言,这些数据提供了在D类β-内酰胺酶中使用avibactam观察到的异常缓慢的可逆性的第一个结构证据。提出了通过D类酶将阿维巴坦酰化和脱酰的机制,并讨论了通过阿维巴坦抑制D类β-内酰胺酶的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号